Insights into treatment goals and review of the current treatment landscape for lower-risk MDS.
This is a video synopsis/summary of a Precision Medicine series featuring Hana Safah, MD, and Jamie Koprivnikar, MD. Safah and Koprivnikar discuss treatment goals and options for lower-risk patients with myelodysplastic syndrome (MDS) who commonly present with anemia, including up to 40% with severe, transfusion-dependent disease. With median survival of 5 to 6 years, maximizing quality of life is paramount.
Minimum aims are avoiding transfusions and anemia symptoms to allow normal daily activities. Emerging data suggest newer agents like luspatercept may provide further benefits by reducing inflammatory signals and mutational burden.
First-line treatment selection depends on disease features. Lenalidomide is used for MDS with del(5q). Immunosuppressive therapy is chosen for higher erythropoietin levels, whereas erythropoiesis-stimulating agents are utilized when levels are under 500 mU/mL. Luspatercept was initially approved after erythropoiesis-stimulating agent failure but has been expanded as up-front therapy for transfusion-dependent, lower-risk MDS. Achieving transfusion independence may improve overall survival. Ongoing research should uncover more molecularly driven and patient-specific strategies.
Video synopsis is AI generated and reviewed by Targeted Oncology™ editorial staff.
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More